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Summary We have examined the enhancement ofcytotoxic effects of cis-diammine-1,l-cyclobutane dicarbox-
ylate platinum(II) (carboplatin) by hyperthermia in HeLa cells using different regimes of timing and sequence.
The results were compared with those obtained with cis-diamminedichloroplatinum(II) (cisplatin). We found
that cisplatin simultaneously combined with heat was the most cytotoxic toward HeLa cells of the various
timing and sequencing conditions studied. On the other hand, for carboplatin, drug treatment immediately
following or during heat exposure showed the greatest effect. Intracellular platinum concentration in HeLa
cells treated with heat before carboplatin showed a 2.75-fold incrase over that in cells treated with the drug
alone. The ratios for carboplatin given before, or during heating, were 0.67 and 1.42 respectively. Simul-
taneous exposure of cells to cisplatin and heat led to a 1.64-fold enhancement in cisplatin accumulation,
compared to 0.92- and 1.24-fold increase for cells treated with cisplatin before and after heat respectively.
Although each drug exposure prior to heat was less cytotoxic toward HeLa cells than any other heat/drug
combination sequences, the platinum concentration wsa less than seen with each drug alone. Even though heat
exposure prior to and during carboplatin showed a similar toxicity, platinum concentration in cells treated
with heat prior to carboplatin was higher than that in cells treated with heat and carboplatin simultaneously.
Thus, increased cytotoxicity cannot always be explained on the basis ofintracellular platinum concentration. It
is clear however that, differing from cisplatin, exposure of cells to heat prior to or during carboplatin
administration results in the greatest cell kill.
cis-Diammine-1,l-cyclobutane dicarboxylate platinum(II) (car-
boplatin) was developed by Harrap et al. (1980) as a second
generation platinum coordination compound. Clinical trials
indicated that this analogue is also highly active against
several human tumour types (Perry et al., 1986; Beer et al.,
1987). Carboplatin differs from cis-diamminedichloroplat-
inum(II) (cisplatin) with respect to pharmacological proper-
ties such as slower drug elimination due to a different
aqueous solubility (Los et al., 199la) and a lower protein
binding capacity (McVie et al., 1985), as a result of structural
changes of cisplatin (Harland et al., 1984; Zwelling, 1987).
The cytotoxicity ofplatinum compounds is due to reaction of
the platinum molecule with nucleophilic sites on the DNA
(Meyn et al., 1980; Terheggen et al., 1988). Carboplatin is
similar to cisplatin with regard to the type of DNA lesions,
which are presumably responsible for the cytotoxicity (Zwell-
ing et al., 1979; Roberts & Friedlos, 1981; Micetich et al.,
1985; Knox et al., 1986; Fichtinger-Schepman et al., 1989;
Teicher et al., 1991).
Hyperthermic enhancement of effects of cisplatin both in
vitro (Wallner et al., 1986; Wallner & Li, 1987; Herman et
al., 1988) and in vivo (Alberts et al., 1980; Overgaard et al.,
1991) has generated considerable interest as a therapy for
malignancy. Carboplatin also seems to be a promising agent
for combination with hyperthermia. Cohen and Robins
(1987) found that carboplatin-induced cytotoxicity was
enhanced by heat, in vitro. Ohno et al. (1991) reported that,
in rats bearing a fibrosarcoma, the simultaneous combination
of carboplatin and whole body hyperthermia produced less
toxicity to normal tissues than a similar treatment using
cisplatin. The former combination therefore produced an
increase in therapeutic gain over that seen with the latter.
With respect to timing and sequencing of cisplatin and heat,
it is generally accepted that simultaneous drug and heat
exposure is most cytotoxic to cultured cells (Wallner et al.,
1986; Wallner & Li, 1987). Similarly, the sequence of heat
and carboplatin exposure is also one factor which affects the
magnitude of the thermal enhancement (Baba et al., 1989).
However, there is a paucity in information as to how timing
and sequence between heat and carboplatin may influence
carboplatin-induced cytotoxicity.
We examined the influence of combining heat and cisplatin
or carboplatin exposure on survival ofHeLa cells. The effects
of heat/drug treatment period and the sequence were
examined. We have also studied the relationship between
carboplatin-mediated cytotoxicity and intracellular platinum
concentrations.
Materials and methods
Drugs
Cisplatin and carboplatin were obtained from Nippon
Kayaku Co. Ltd. (Tokyo, Japan) and Bristol-Myers Squibb
Co. (Tokyo, Japan), respectively. The compounds were dis-
solved just before use in Hanks' balanced salt solution
(HBSS), to obtain the designated concentrations.
Cells
The HeLa cells we used were maintained in a monolayer
culture in Eagle's minimal essential medium (Nissui Phar-
maceutical Co. Ltd., Tokyo, Japan) containing 292 mg ml-'
of L-glutamine, 100 unitsml-I of penicillin, 0.1 mgml-' of
streptomycin and 0.04 mgml-' of gentamycin supplemented
with 10.0% heat inactivated fetal calf serum (GIBCO
Laboratories, NY, USA). Cultures were routinely incubated
at 37.0°C in a humidified atmosphere of 5.0% CO2 in air.
Heat/drug exposure
Exponentially growing HeLa cells were trypsinised, cen-
trifuged and resuspended in HBSS in a glass test tube
(approximately 5 x 105/0.4 ml HBSS). To investigate the
time-dependent response of the cells to treatment, they were
exposed to a temperature of 42.8°C for the designated time,
before, during or after treatment with 33.2 gM cisplatin or
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265gM carboplatin, for the same period. To investigate heat/
drug sequencing, the cells were exposed to heat for 30 min at
42.8°C at varying times before, during or after the start of
treatment with either cisplatin or carboplatin at concentra-
tions of 33.2gM or 265 JLM, respectively, for 30 min. These
concentrations were equal to the IC50s for 30 min treatment
with the drugs as determined in dose response survival
experiments (Figure 1). The heat exposure involved placing
cells in a glass tube and immersing the tube, tightly sealed
with a sterile rubber stopper and punctured with needles for
inflow and outflow of air, in a water bath heated to a precise
temperature. The temperature of the water bath was auto-
matically maintained at 42.8°C within ± 0.1°C. After drug
treatments, the cells were washed three times with fresh,
drug-free HBSS heated to the same temperature.
Survival experiments
Cell survival assay was carried out using the colony forma-
tion method. After heat/drug exposure, the cells were washed
three times with HBSS. The number of cells in each group
was counted and the cells were plated into 60-mm sterile
plastic culture dishes (Corning No. 25010, USA), in triplicate
at two dilutions (300 and 500 cells for control; 1,000 and
3,000 cells for each treatment group) and incubated in a
humidified atmosphere with 5.0% CO2 at 37.0°C. After 1
week, the colonies were fixed with ethanol, and stained with
Giemsa solution. Colonies of 50 or more cells were counted.
Each experiment was repeated three times.
Determination ofintracellular platinum concentrations
After treatment with 33.2JLM of cisplatin or 265ylM of carbo-
platin for 30 min, before, during or after 30 min exposure to
heat with an interval of 30 min, the cells were placed on ice
and washed three times with drug-free HBSS to remove
extracellular drug. The cells were then stored in a freezer.
The final cell pellet collected was sonicated and the mass of
intracellular platinum was determined by atomic absorption
spectrophotometry in a pyrocoated graphite cuvette (Hitachi
Model 180-7444, Hitachi, Ltd., Tokyo, Japan), using a
polarised flameless atomic absorption spectrophotometer
(Zeeman Model Z-8000, Hitachi, Ltd., Tokyo, Japan) (Leroy
et al., 1977). Platinum atomic absorption standard solution
(No. P-6401, Sigma Co., St. Louis, MO, USA) was diluted to
two different concentrations and these were run with each
experiment for calibration. The concentration of platinum
was expressed as ytg/107 cells.
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Statistical analysis
The Welch-Aspin t-test was used to determine significance of
the difference in slopes of the time-dependent survival curves
(Snedecor & Cochran, 1989; Krag et al., 1990). Comparisons
of intracellular platinum concentrations between treatment
groups were made using Student's t-test. When the value of P
was less than 0.05, the difference was considered to be statis-
tically significant.
Results
Effects ofdrug alone and drug/heat combination sequencing on
HeLa cells
The value of plating efficiency for control cells was
92.0 ± 7.8%. All the time-dependent survival response curves
showed exponential inhibition of the clonogenic activity of
HeLa cells. The slopes of time-heat/drug response curves
were calculated for cisplatin and carboplatin. The regression
coefficients from our data gave slopes of - 0.0430 and
- 0.1331 min-' for cisplatin alone, and for simultaneous
treatment with cisplatin and heat, respectively. Hence, heat
produced a 3.10-fold increase in the slope. The corresponding
estimates for carboplatin were - 0.0154 and - 0.0456 min-'.
Heat therefore gave a 2.96-fold increase in the slope, a value
similar to that for cisplatin. The concomitant exposure to
heat and cisplatin showed a greater inhibition of the surviv-
ing fraction than seen in any of the other groups treated with
cisplatin, with significant differences in the slopes (P<0.01),
as shown in Figure 2. In case of carboplatin, when exposure
to heat was during or prior to carboplatin treatment, the
effect on the surviving fraction was greatest, with statistically
significant differences in the slopes (P<0.01), as shown in
Figure 3.
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Figure 1 Single effect of cisplatin (0) or carboplatin (A) against
HeLa cells for 30 min. Points, means of three independent
experiments; bars, s.d.
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Figure 2 Effects of heat alone, cisplatin alone or heat/cisplatin
combination on survival of HeLa cells. Symbols show the follow-
ing treatment: *, heat (42.8'C) alone; 0, 33.2 gM of cisplatin
alone; *, cisplatin followed by heat at 30min intervals; A, heat
followed by cisplatin at 30 min intervals; and *, simultaneous
treatment ofcisplatin and heat. The cells were treated with either
cisplatin or heat for 30 min. Points, means of triplicate
experiments; bars, s.d.
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Figure 5 Effects of treatment sequence of heat and carboplatin
on survival of HeLa cells. Cells were exposed to a 42.8°C
temperaturre for 30 min at varying times before (negative time
values), during (time 0), and after (positive time values) a 30 min
carboplatin treatment at 265JIM. Points, means of three indepen-
dent experiments; bars, s.d.
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Figure 3 Effects of heat alone, carboplatin alone or heat/
carboplatin combination on survival of HeLa cells. Symbols show
the following treatment: *, heat (42.8°C) alone; A, 265JIM of
carboplatin alone; 0, carboplatin followed by heat at 30min
intervals; A, heat followed by carboplatin at 30min intervals;
and *, simultaneous treatment of carboplatin and heat. The cells
were treated with either carboplatin or heat for 30 min. Points,
means of triplicate experiments; bars, s.d.
Effects of treatment sequence on cell killing by heat and drugs
Figures 4 and 5 show the effects of drug-heat sequencing and
duration on the cytotoxicity ofcombined treatment with heat
and cisplatin or carboplatin, respectively. When the cells were
exposed to heat during a 30 min exposure to cisplatin, cell
killing was greatest. Cisplatin and heat applied with various
time intervals between them had less cytotoxic effect than
simultaneous treatment. On the other hand, heat treatment
immediately prior to or during exposure of carboplatin was
the most cytotoxic. Carboplatin administered prior to heat
had less cytotoxic effect.
Correlation between cytotoxicity and intracellular platinum
concentrations in HeLa cells
Table I shows the intracellular platinum concentration of
each combination of heat and drugs, compared with cells
treated with the drug alone. For cisplatin, a significantly
higher platinum concentration was seen in cells exposed to
heat and cisplatin simultaneously, compared with cells
treated with heat following or prior to cisplatin (P<0.05). In
the case of carboplatin, cells treated with heat before the
drug had intracellular concentrations of platinum which were
2.75-fold higher than seen in the drug alone treated group
(P<0.01). However, in the case of carboplatin exposure
prior to heat treatment, there was a decrease in platinum
concentrations to levels lower than seen with the drug alone.
Discussion
Heat exposure markedly enhanced the cytotoxicity induced
by either cisplatin or carboplatin, findings comparable to
results seen in other studies (Micetich et al., 1985; Cohen &
Robins, 1987). Our results showed that cisplatin cytotoxicity
was most enhanced by heat when these treatments were given
simultaneously. Several previous studies have also shown that
the simultaneous exposure of cisplatin and heat resulted in the
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Figure 4 Effects of treatment sequence of heat and cisplatin on
survival of HeLa cells. Cells were exposed to a 42.8°C
temperature for 30 min at varying times before (negative time
values), during (time 0), and after (positive time values) a 30 min
cisplatin treatment at 33.2 JIM. Points, means of three indepen-
dent experiments; bars, s.d.
Table I The relative values ofintracellular concentrations ofplatinum
in HeLa cells exposed to heat before, during and after cisplatin/
carboplatin treatment at 30 min intervals
Intracellular platinum concentration'
Treatment Cisplatinb Carboplatinc
Drug + Heatd 1.57 ± 0.11 (1.64e) 2.78 ± 0.14 (1.42)
Drug->Heatd 0.88 ± 0.09 (0.92) 1.31 ± 0.07 (0.67)
Heat->Drugd 1.15 ± 0.08 (1.24) 5.38 ± 0.16 (2.75)
"jAg/07 cells;b33.2JM;C265JIM.dThecells wereexposed to eachdrug
or to heat for 30 min. eRelative value when the intracellular platinum
concentration in HeLa cells treated with each drug alone was 1.0.
greatest cytotoxic effect (Wallner et al., 1986; Wallner & Li,
1987). On the other hand, in the case of carboplatin, heat
exposure immediately prior to or during treatment with car-
boplatin had the greatest effect on cell survival. Cohen and
Robins (1987) have suggested that heat should be given
during or immediately prior to carboplatin, in a clinical
setting, based on data obtained in laboratory studies.
The mechanisms by which hyperthermia can increase the
cytotoxicity of chemotherapeutic agents include increased
drug levels in cells (Hahn & Strande, 1976) and hyperthermia
induced inhibition of DNA repair (Meyn et al., 1979).
Moreover, for antitumour alkylating agents such as cisplatin
analogues, a linear relationship was found between DNA
cross-link formation and the dose of drugs. The rate of DNA
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adduct formation at elevated temperature was higher than
seen at normal temperature (Meyn et al., 1980; Los et al.,
1982). With regard to the first mechanism mentioned above,
other investigators have reported that heat increases the
intracellular platinum concentration in cells exposed to cis-
platin in vitro (Wallner et al., 1986; Los et al., 1991b) and in
vivo (Alberts et al., 1980) and our data show that the heat-
induced increase in intracellular platinum concentrations cor-
relates with decrease in the survival of HeLa cells.
However, the decrease in survival of HeLa cells which we
have observed cannot be explained by increased platinum
concentrations alone. Firstly, although heat exposure prior to
and during carboplatin was equally toxic (Figure 3), the
uptake ofcarboplatin into cells was higher after heat prior to
carboplatin treatment than after simultaneous heat and car-
boplatin treatment. Simultaneous heat and carboplatin pro-
duced a 2.96-fold greater effect on cell survival but only a
1.42-fold increase in intracellular platinum levels (Table I).
On the other hand, the increased effects seen for heat prior to
carboplatin were almost identical (2.85 vs 2.75).
Secondly, although the drug given alone and immediately
prior to heat exposure were almost equally cytotoxic (Figures
2 and 3), platinum levels in cells treated with heat prior to
drug exposure were lower than for drug alone (Table I). The
first point may mean that the carboplatin-induced cytotox-
icity could be a result of an increased rate of DNA lesion
formation during heating. Another possible explanation is
that heat increases cell membrane permeability to drugs
(Arancia et al., 1989) and the membrane transport of drugs
(Hahn et al., 1975) thereby altering cellular metabolism
(Hahn & Shiu, 1983). Based on these reasons, the overall
kinetics of carboplatin may change. The second observation
above could possibly be explained if heat increases drug
excretion before formation of DNA lesions. Micetich et al.
(1985) have shown that DNA adduct formation reaches a
maximum several hours after cisplatin or carboplatin ex-
posure. Although the time course for carboplatin is thought
to be different from that for cisplatin (Micetich et al., 1985;
Knox et al., 1986; Los et al., 19991b), the relatively short
intervals which we used in our study did not show any
difference in effects between carboplatin before heat treat-
ment and cisplatin before heat treatment.
Various side effects result from combined use of heat and
anticancer drugs in a clinical setting, including increased
nephrotoxicity by cisplatin (Gonzales-Vitale et al., 1977;
Campbell et al., 1983) and myelosuppression by carboplatin
(Curt et al., 1983; Stemnberg et al., 1985). However, optimal
use of heat/drug scheduling shows promise for combination
treatment of cancer patients, as reported by Baba et al.
(1989). Our findings may be helpful in the design of com-
bined treatments with hyperthermia and cisplatin analogues.
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